”A very positive fiscal year 2018/2019 is summarized in the annual report. For example, we have presented positive results from clinical trials in collaboration with leading oncologists, that has highlighted the value of DiviTum before and during treatment. Biovica has now finalized eight clinical trials within breast cancer with over 1 000 patients. Together with ongoing studies this will serve as a good foundation for regulatory approval, inclusion in guidelines and reimbursement. The development of our FDA-version of DiviTum has been finalized. Also, Biovica has established a subsidiary business in the US. We look forward to an exciting year 2019/2020 where we will take steps towards contributing to best possible treatment from day one!” said Anders Rylander, CEO at Biovica.